AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey (collectively, AmeriHealth) are updating the previously announced changes to drug preferences and step therapy requirements. Providers should note the following additional changes affecting intravenous immune globulin (IVIG) products.
Effective January 1, 2027, Yimmugo® and Qivigy® will be considered non-preferred IVIG products. Yimmugo is currently preferred, while Qivigy is not currently included on the preferred drug list.
Providers should review this change when selecting IVIG therapy to help minimize potential disruption in member care.
26-0263